HEALTH● LOWAug 14 · Aug 14, 2026, 3:27 PM
Acurx outlines 20-patient PATHFINDER start in Q4 as FDA stays open to a single Phase III ASPIRE for ibezapolstat
Seeking Alpha Tech
Acurx plans to start its 20-patient PATHFINDER trial in Q4, with the FDA remaining open to a single Phase III ASPIRE trial for ibezapolstat. This indicates progress in the development and regulatory pathway for the drug.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Health
HEALTH1h agoAgostina Hein withdrew from the South American Games due to her recovery after an appendicitis operationClarínHEALTH1h agoCourt records indicate insanity defense for woman charged in Hoffman deathkctv5.com · United StatesHEALTH1h agoT - Boz Steps Back From Tour to Focus on Her Healththeroot.com · United StatesHEALTH1h agoUnion de Reyes Faces Surge in Fever Cases Amid Arbovirus Spread and Fumigation Challengescubaheadlines.com · Cuba